The DOI matches its Crossref record; 275 of the 279 references it cites were found in a registry or an index.
Targeting tumor extracellular matrix with nanoparticles to circumvent therapeutic resistance
Abstract
Each stage of tumor development is intrinsically linked to the tumor microenvironment (TME), wherein the extracellular matrix (ECM) serves as a vital and abundant component in tumor tissues. The ECM is a non-cellular, three-dimensional macromolecular network scaffold that provides structural support to cells, stores bioactive molecules, and mediates signaling pathways through specific binding to cell surface receptors. Moreover, the ECM in tumor tissues plays a crucial role in impeding drug diffusion and resisting apoptosis induced by conventional anti-cancer therapies that primarily target cancer cells. Therefore, directing attentions towards the tumor ECM can facilitate the identification of novel targets and the development of new therapies. This review aims to summarize the composition, structure, remodeling, and function of tumor ECM, its association with drug resistance, and current targeting strategies, with a specific emphasis on nanoparticles (NPs).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have demonstrated that the hardened ECM network considerably restricts the penetration of therapeutic drugs, ultimately affecting their efficacy (36).”
From Matrix mechanical remodeled carrier-free nanosystem for programmable closed-loop reversal of liver fibrosis via STING alkylation (2025) · cites this paper as [36]
Citations
Cites
Items 201–275 of 275
Sun, Y., Lyu, B., Yang, C. Q., He, B., Zhang, H., Wang, X., Zhang, Q., & Dai, W. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.08.020 · Cited by 65
Eke, I., Storch, K., Krause, M., & Cordes, N. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0344 · Cited by 63
Dandelion‐Like Tailorable Nanoparticles for Tumor Microenvironment Modulation
Guo, Q., He, X., Li, C., He, Y., Peng, Y., Zhang, Y., Lü, Y., Chen, X., Zhang, Y., Chen, Q., et al. (2019) · Advanced Science · doi:10.1002/advs.201901430 · Cited by 63
Zhou, Y., Yu, Q., Qin, X., Bhavsar, D., Yang, L., Chen, Q., Zheng, W., Chen, L., & Liu, J. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b02261 · Cited by 63
Pretargeting using peptide nucleic acid
Rusckowski, M., Qu, T., Chang, F., & Hnatowich, D. J. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971215)80:12+ · Cited by 63
Eikenes, L., Tufto, I., Schnell, E. A., Bjørkøy, A., & Davies, C. D. L. (2010) · PubMed · Cited by 62
Tune, B. X. J., Sim, M. S., Poh, C. L., Guad, R. M., Choy, K. W., Hazarika, I., Das, A., Gopinath, S. C. B., Rajan, M., Sekar, M., et al. (2022) · Journal of Oncology · doi:10.1155/2022/3249766 · Cited by 61
Self-citationECM-targeting bacteria enhance chemotherapeutic drug efficacy by lowering IFP in tumor mouse models
Kim, J.-S., Park, J.-E., Choi, S.-H., Kang, S. W., Lee, J. H., Lee, J.-S., Shin, M., & Park, S.-H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.001 · Cited by 61
Wang, L., Li, C., Wang, J., Yang, G., Lv, Y., Fu, B., Jian, L., Ma, J., Yu, J., Yang, Z., et al. (2022) · Advanced Materials · doi:10.1002/adma.202203518 · Cited by 60
Proinvasive extracellular matrix remodeling in tumor microenvironment in response to radiation
Yoo, K.-C., Suh, Y., An, Y., Lee, H., Jeong, Y. J., Uddin, N., Cui, Y., Roh, T. H., Shim, J., Chang, J. H., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0199-y · Cited by 60
TRPV4 Mechanotransduction in Fibrosis
Adapala, R. K., Katari, V., Teegala, L. R., Thodeti, S., Paruchuri, S. M., & Thodeti, C. K. (2021) · Cells · doi:10.3390/cells10113053 · Cited by 59
Cordes, N., & Beinke, C. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.1.570 · Cited by 58
Peptide‐Modified Dendrimer Nanoparticles for Targeted Therapy of Colorectal Cancer
Carvalho, M. R., Carvalho, C. R., Maia, F. R., Caballero, D., Kundu, S. C., Reis, R. L., & Oliveira, J. M. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900132 · Cited by 58
Proteoglycans and Immunobiology of Cancer—Therapeutic Implications
Tzanakakis, G. N., Neagu, M. T., Tsatsakis, A. M., & Nikitovic, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00875 · Cited by 57
Wang, K., Tu, Y., Wang, Y., Zong, Q., Xiao, X., Yang, R., Jiang, X., & Yuan, Y. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b21525 · Cited by 57
Dong, F., Eibach, M., Bartsch, J. W., Dolga, A. M., Schlomann, U., Conrad, C., Schieber, S., Schilling, O., Biniossek, M. L., Culmsee, C., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov042 · Cited by 57
Deng, Y., Chakraborty, P., Jolly, M. K., & Levine, H. (2021) · Cancers · doi:10.3390/cancers13071609 · Cited by 57
Human fibronectin extra domain B as a biomarker for targeted therapy in cancer
Lieverse, R. I. Y., Marcus, D., van der Wiel, A. M.-M. A., Limbergen, E. J. V., Theys, J., Yaromina, A., Lambin, P., & Dubois, L. J. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12705 · Cited by 56
Hooper, A. T., Marquette, K., Chang, C.-P. B., Golas, J., Jain, S., Lam, M., Guffroy, M., Leal, M., Falahatpisheh, H., Mathur, D., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0099 · Cited by 54
Cleavable collagenase-assistant nanosonosensitizer for tumor penetration and sonodynamic therapy
Yin, T., Chen, H., Ma, A.-Q., Pan, H., Chen, Z., Tang, X., Huang, G., Liao, J., Zhang, B., Zheng, M., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121992 · Cited by 53
Guo, F., Du, Y., Wang, Y., Wang, M., Wang, L., Yu, N., Luo, S., Wu, F., & Yang, G. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.128658 · Cited by 53
Multiscale relationships between fibronectin structure and functional properties
Bradshaw, M. J., & Smith, M. L. (2013) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.08.027 · Cited by 52
β1 integrin targeting to enhance radiation therapy
Nam, J.-M., Chung, Y., Hsu, H. C., & Park, C. C. (2009) · International Journal of Radiation Biology · doi:10.3109/09553000903232876 · Cited by 52
You, G.-R., Cheng, A., Lee, L., Huang, Y.-C., Liu, H., Chen, Y.-J., & Chang, J. T. (2019) · BMC Cancer · doi:10.1186/s12885-018-5243-3 · Cited by 52
Huang, H., Chen, L.-Q., Sun, W. Y., Du, H., Dong, S., Ahmed, A. M. Q., Cao, D., Cui, J.-H., Zhang, Y., & Cao, Q. (2020) · Theranostics · doi:10.7150/thno.47446 · Cited by 51
Wu, J., Li, Y., Dang, Y.-Z., Gao, H., Jiang, J., & Chen, Z. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0618 · Cited by 50
Cheng, Y., Lin, L., Li, X., Lu, A., Hou, C., Wu, Q., Hu, X., Zhou, Z., Chen, Z., & Tang, F. (2021) · Cancer Cell International · doi:10.1186/s12935-020-01727-5 · Cited by 46
Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies
Diazzi, S., Tartare‐Deckert, S., & Deckert, M. (2020) · Cancers · doi:10.3390/cancers12061364 · Cited by 44
Escalona, R. M., Bilandzic, M., Western, P. S., Kadife, E., Kannourakis, G., Findlay, J. K., & Ahmed, N. (2020) · BMC Cancer · doi:10.1186/s12885-020-07274-6 · Cited by 43
Saw, P. E., Xu, X., Kang, B. R., Lee, J., Lee, Y. S., Kim, C., Kim, H., Kang, S.-H., Na, Y. J., Moon, H. J., et al. (2020) · Theranostics · doi:10.7150/thno.44948 · Cited by 43
An, B., Abbonante, V., Xu, H., Gavriilidou, D., Yoshizumi, A., Bihan, D. G., Farndale, R. W., Kaplan, D. L., Balduini, A., Leitinger, B., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.674507 · Cited by 42
Vega, M. E., & Schwarzbauer, J. E. (2016) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2016.03.014 · Cited by 41
Park, G. B., Chung, Y. H., & Kim, D. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000472 · Cited by 41
αvβ3 Integrin Mediates Radioresistance of Prostate Cancer Cells through Regulation of Survivin
Wang, T., Huang, J., Vue, M., Alavian, M. R., Goel, H. L., Altieri, D. C., Languino, L. R., & FitzGerald, T. J. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0544 · Cited by 41
Feng, Y., Liao, Z., Zhang, H., Xie, X., You, F., Liao, X., Wu, C., Zhang, W., Yang, H., & Liu, Y. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.139506 · Cited by 41
Dendritic Cell Migration Is Tuned by Mechanical Stiffness of the Confining Space
Choi, Y., Kwon, J., & Cho, Y. (2021) · Cells · doi:10.3390/cells10123362 · Cited by 40
Collagen-coated microparticles in drug delivery
Sehgal, P. K., & Srinivasan, A. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903025736 · Cited by 39
Tian, Y., Cheng, T., Sun, F., Zhou, Y., Yuan, C., Guo, Z., & Wang, Z. (2024) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2024.103124 · Cited by 38
Ongaro, T., Matasci, M., Cazzamalli, S., Gouyou, B., Luca, R. D., Neri, D., & Villa, A. (2018) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2018.12.004 · Cited by 38
Closset, L., Gultekin, O., Salehi, S., Sarhan, D., Lehti, K., & Gonzalez‐Molina, J. (2023) · Matrix Biology · doi:10.1016/j.matbio.2023.07.003 · Cited by 36
The Role of Laminin-1 in the Modulation of Radiation Damage in Endothelial Cells and Differentiation
Rose, R. W., O'Hara, M. D., Williamson, S. K., & Grant, D. S. (1999) · Radiation Research · doi:10.2307/3580045 · Cited by 36
Keller, S. B., & Averkiou, M. A. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00422 · Cited by 35
Hoshiba, T. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.07.022 · Cited by 33
Enzyme-Triggered Size-Switchable Nanosystem for Deep Tumor Penetration and Hydrogen Therapy
He, Y., Tian, X., Fan, X., Gong, X., Tan, S., Pan, A., Liang, S., Xu, H. X., & Zhou, F. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c18184 · Cited by 33
Integrin β1 regulates the invasion and radioresistance of laryngeal cancer cells by targeting CD147
Li, L., Dong, X., Peng, F., & Shen, L. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0578-z · Cited by 32
Laminin-derived peptides: Applications in drug delivery systems for targeting
Negishi, Y., & Nomizu, M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.017 · Cited by 31
Proteoglycans, key regulators of cell–matrix dynamics
Schaefer, L. (2014) · Matrix Biology · doi:10.1016/j.matbio.2014.05.001 · Cited by 31
TIMP3 regulates osteosarcoma cell migration, invasion, and chemotherapeutic resistances
Han, X., Li, Y., Mo, H., Li, K., Lin, D., Zhao, C., Zhao, J., & Tang, T. (2016) · Tumor Biology · doi:10.1007/s13277-015-4757-4 · Cited by 30
Autologous Skin Fibroblast‐Based PLGA Nanoparticles for Treating Multiorgan Fibrosis
Long, Q., Liu, Z., Shao, Q., Shi, H., Huang, S., Jiang, C., Qian, B., Zhong, Y., He, X., Xiang, X., et al. (2022) · Advanced Science · doi:10.1002/advs.202200856 · Cited by 29
Ebelt, N. D., Zamloot, V., Zuniga, E., Passi, K. B., Sobocinski, L. J., Young, C. A., Blazar, B. R., & Manuel, E. R. (2021) · Cancers · doi:10.3390/cancers13143565 · Cited by 29
Ultrasmall gold nanosatellite-bearing transformable hybrid nanoparticles for deep tumor penetration
Son, S., Deepagan, V. G., Shin, S., Ko, H., Min, J., Um, W., Jeon, J., Kwon, S., Lee, E. S., Suh, M., et al. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.08.019 · Cited by 28
Liu, J., Meng, Z., Xu, T., Kuerban, K., Wang, S., Zhang, X., Fan, J., Ju, D., Tian, W., Huang, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845217 · Cited by 27
Jiang, Y., Huang, J., Huang, Z., Li, W., Tan, R., Li, T., Chen, Z., Tang, X., Zhao, Y., Qiu, J., et al. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110866 · Cited by 24
TIMP-1-Mediated Chemoresistance via Induction of IL-6 in NSCLC
Xiao, W. L., Wang, L., Howard, J. H., Kolhe, R. B., Rojiani, A. M., & Rojiani, M. V. (2019) · Cancers · doi:10.3390/cancers11081184 · Cited by 23
Abdollahiyan, P., Oroojalian, F., Baradaran, B., de la Guárdia, M., & Mokhtarzadeh, A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.002 · Cited by 19
Liu, J., Pan, D., Huang, X., Wang, S., Chen, H., Zhu, Y. Z., & Ye, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1225483 · Cited by 19
Tzanova, M. M., Randelov, E., Stein, P. C., Hiorth, M., & di Cagno, M. P. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121116 · Cited by 19
Sanford, M. (2014) · BioDrugs · doi:10.1007/s40259-014-0104-3 · Cited by 18
Wang, Z., Wang, Y., Sun, X., Zhou, J., Chen, X., Xi, J., Fan, L., Han, J., & Guo, R. H. (2022) · Small · doi:10.1002/smll.202200588 · Cited by 18
Dalzon, B., Lebas, C., Jimenez, G., Gutjahr, A., Terrat, C., Exposito, J., Verrier, B., & Lethias, C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167663 · Cited by 17
Negishi, Y., Hamano, N., Omata, D., Fujisawa, A., Manandhar, M., Nomizu, M., & Aramaki, Y. (2011) · Results in Pharma Sciences · doi:10.1016/j.rinphs.2011.10.001 · Cited by 16
Brundel, D. H. S., Feeney, O. M., Nowell, C. J., Suys, E. J. A., Gracia, G., Kaminskas, L. M., McIntosh, M. P., Kang, D. W., & Porter, C. J. H. (2021) · Nanomedicine · doi:10.2217/nnm-2020-0433 · Cited by 14
Cho, W., Kim, M. S., Lee, K.-H., Park, S. J., Shin, H.-J., Lee, Y. J., Kim, S. B., Son, Y., & Kim, C. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.102141 · Cited by 13
Use of an extracellular matrix material as a vaccine carrier and adjuvant.
Suckow, M. A., Hall, P., Wolter, W., Sailes, V., & Hiles, M. C. (2008) · PubMed · Cited by 12
Hill, S. L., & Davies, A. J. (2018) · Future Oncology · doi:10.2217/fon-2017-0574 · Cited by 12
Hsu, S., Wu, N.-P., Lu, Y.-C., & Ma, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081523 · Cited by 12
TIMP-1 Dependent Modulation of Metabolic Profiles Impacts Chemoresistance in NSCLC
Xiao, W., Ahluwalia, P. K., Wang, L., Howard, J. H., Kolhe, R. B., Rojiani, A. M., & Rojiani, M. V. (2022) · Cells · doi:10.3390/cells11193036 · Cited by 10
Wu, Y., Li, Y., Hu, Z., Li, Y., Zhang, S., Bao, X., Zhou, Y. J., Gao, Y., Li, Y., & Zhang, Z. (2024) · Advanced Materials · doi:10.1002/adma.202310982 · Cited by 10
Self-citationAbdel-Rafei, M. K., Azab, K. S., El-Sayyad, G. S., Askar, M. A., Elkodous, M. A., Fatih, N. M. E., Tawill, G. E., & Thabet, N. M. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220816123508 · Cited by 7
Mechanisms of deformation and drug release of targeting polypeptides based on fibronectin induction
Zhong, W., Yue, K., Wang, A., Zhang, G., Wang, J., Wang, L., Wang, H., Zhang, H., & Zhang, X. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.112836 · Cited by 7
The effect of laminins on chemoresistance of colorectal cancer cells
Maltseva, D. V., Захарова, Г. С., Rodin, S., & Tonevitsky, A. (2018) · Russian Chemical Bulletin · doi:10.1007/s11172-018-2344-8 · Cited by 6
Collagen I confers gamma radiation resistance
Azorin, E., González-Martínez, P. R., & Azorı́n, J. (2012) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2012.03.039 · Cited by 6
Suckow, M. A., & Hiles, M. C. (2022) · Anticancer Research · doi:10.21873/anticanres.16168 · Cited by 6
Guo, X., Yang, L., Deng, C., Ren, L., Li, S., Zhang, X., Zhao, J. L., & Yue, T. (2024) · Nanoscale · doi:10.1039/d3nr06305d · Cited by 6
Elad, S. T., Vilensky, R., Ben-Asher, N., Логвина, Н. А., Zalk, R., Zussman, E., & Engel, L. (2025) · Nanoscale · doi:10.1039/d4nr05508j · Cited by 6
Flagged first, then by citations
4 of the 279 references couldn’t be matched to a known paper.
Research works printed but not linked: 7
- Fukazawa, 2015, Laminin β3 expression as a prognostic factor and a predictive marker of chemoresistance in colorectal cancer, Jpn. J. Clin. Oncol., 45, 533
- Li, 2022, Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of laminin α5/FAK signaling, Commun. Biol., 5, 1
- Toth, 2019, Hypoxia-induced PIM kinase and laminin-activated integrin α6 mediate resistance to PI3K inhibitors in bone-metastatic CRPC, Am. J. Clin. Exp. Urol., 7, 297
- Colak, 2017, Targeting TGF-β signaling in Cancer, trends, Cancer, 3, 56
- Peng, 2022, Local release of TGF-β inhibitor modulates tumor-associated neutrophils and enhances pancreatic Cancer response to combined irreversible electroporation and immunotherapy, Adv Sci (Weinh), 9
- Nguyen, 2019, YAP/TAZ signaling and resistance to Cancer therapy, trends, Cancer, 5, 283
- Ogawa, 2021, Three distinct stroma types in human pancreatic Cancer identified by image analysis of fibroblast subpopulations and collagen, clinical, Cancer Res., 27, 107
Cited by
Sorted by citations
Yang, C., Li, S., & Wang, L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02443-2 · Cited by 52
Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape
Salgado-Pascual, A., Zalba, S., Lasarte, J. J., & Garrido, M. J. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115760 · Cited by 16
STAR Therapy: Spatiotemporal Antitumor Regimen via a Size‐Gated DNA Hydrogel Drug Delivery System
Feng, C. Q., Yang, Z., Lan, Y., Fu, X., Zhang, W., Lu, W., Huang, Z., Wang, Y., Zhang, Z., Fan, J., et al. (2026) · Advanced Materials · doi:10.1002/adma.202517487 · Cited by 8
Self-citationHan, H., Yu, D., Liu, Y., Jia, H., & Liu, W. (2025) · Science Advances · doi:10.1126/sciadv.adz4126 · Cited by 7
“Studies have demonstrated that the hardened ECM network considerably restricts the penetration of therapeutic drugs, ultimately affecting their efficacy ( 36 ).”
Dang, B.-T. N., Pham, K., Nguyen, A.-H., Park, J., Kwon, T. K., Kang, J., Jeong, J., & Yook, S. (2025) · Biomaterials Research · doi:10.34133/bmr.0289 · Cited by 7
Metadata
- Authors
- Ding, X., Liang, Y., Zhou, S., Wu, Y., Sałata, P., Mikolajczk-Martinez, A., Khosrawipour, V., & Zhang, Z.
- Affiliations
- Fudan University (CN)
- Wrocław University of Environmental and Life Sciences (PL)
- Corresponding author
- Khosrawipour, Veria
- Zhang, Zhiwen
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2025-07
- Volume
- 383
- Pages
- 113786
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W4409885575
- Cited by
- 20
- References
- 279
- Citations by year
- 2026: 15 · 2025: 5
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Controlled Release (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Science and Technology of the People's Republic of China
- National Key Research and Development Program of China (2023YFE0104300)
- National Natural Science Foundation of China (32271461)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Keywords
- tumor extracellular matrix, nanoparticles, drug resistance, tumor microenvironment, extracellular matrix remodeling, apoptosis resistance, cancer therapy
- MeSH terms
- Animals, Antineoplastic Agents, Extracellular Matrix, Humans, Neoplasms, Drug Delivery Systems, Drug Resistance, Neoplasm, Nanoparticles, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
